TGTX stock up on positive phase I data for subcutaneous Briumvi
- Posted on June 4, 2026
- By Bing News
- 0 Views
- 1 min read
TGTX stock up on positive phase I data for subcutaneous Briumvi
Shares of TG Therapeutics TGTX were up 9.5% yesterday after the company announced positive data from a phase I study evaluating the subcutaneous (“SC”) formulation of its sole marketed drug, Briumvi (ublituximab-xiiy). Briumvi, an anti-CD20 monoclonal antibody, is currently approved for the treatment of adult patients with relapsing forms of multiple sclerosis (“RMS”) as an intravenous (IV) formulation. The phase I study evaluated the...
